Denali Therapeutics Inc.
NASDAQ:DNLIBiotechnology
+$0.09 today
- Market cap
- $2.95B
- Beta
- 1.01
- P/E (TTM)
- -8.7
- EPS (TTM)
- -$2.72
Volume 2.37M
Average 1.84M
DNLI Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Denali Therapeutics Inc.NASDAQ: DNLI
Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026
Weighted avg shares growth accelerates
Q2 FY2026 weighted avg shares of 187.31M shares rose 9.3% year over year, ahead of the +5.8% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.4% from the prior quarter. Over 3 fiscal years it compounded at +11.8% a year.
Context
- Weighted avg shares increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +9.3% holds above the trailing-twelve-month pace of +5.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 175.46M USD
- Year-over-year change
- +6.7%
- 4-year CAGR
- +9.6%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 175.46M | +6.7% |
| FY2024 | 2024-12-31 | 164.47M | +19.7% |
| FY2023 | 2023-12-31 | 137.37M | +9.4% |
| FY2022 | 2022-12-31 | 125.53M | +3.3% |
| FY2021 | 2021-12-31 | 121.52M | — |
Weighted Avg Shares vs competitors
How DNLI compares with its peers on the latest reported figures
- DNLI's LTM Jun 2026 weighted avg shares of 180.46M shares is the highest of the 11 companies compared; the peer median is 102.39M shares.
- Its year-over-year change of +5.8% is the 8th highest of 11, against a peer median of +29.5%.
- Over three fiscal years its annual growth of +11.8% compares with a peer median of +22.6%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Jun 2026 | 180.46M | +5.8% | +11.8% | |
NMRANeumora Therapeutics, Inc. Common Stock | LTM Mar 2026 | 166.7M | +4.0% | +2.4% |
| LTM Sep 2026 | 164.62M | +3.4% | +4.1% | |
| LTM Jun 2026 | 131.06M | +31.1% | +34.0% | |
| LTM Sep 2026 | 108.82M | +29.3% | +12.4% | |
| LTM Mar 2026 | 104.14M | +6.5% | +7.7% | |
| LTM Sep 2026 | 100.65M | +1.1% | +1.3% | |
| LTM Mar 2026 | 79.93M | +69.4% | +35.9% | |
RAPPRapport Therapeutics, Inc. Common Stock | LTM Mar 2026 | 41.9M | +115.2% | +32.7% |
| LTM Sep 2026 | 27.42M | +29.8% | +94.2% | |
| LTM Jun 2026 | 4.71M | +249.7% | +80.2% | |
| Peer median (excluding DNLI) | 102.39M | +29.5% | +22.6% | |
Competitors are the stored peer set for DNLI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 48.66M | 108.46M | 330.53M | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 11.18M |
| Gross Profit | 48.66M | 108.46M | 330.53M | 0 | (11.18M) |
| Gross Margin | 100.0% | 100.0% | 100.0% | — | — |
| Research & Development | 265.35M | 358.73M | 423.88M | 396.44M | 418.78M |
| Selling, General & Admin | 79.06M | 90.48M | 103.35M | 105.44M | 97.1M |
| Operating Expenses | 344.41M | 449.21M | 527.23M | 487.34M | 544.16M |
| Depreciation & Amortization | 8.59M | 10.38M | 16.73M | 8.99M | 14.81M |
| EBITDA | (282.56M) | (315.59M) | (128.47M) | (492.89M) | (497.63M) |
| EBITDA Margin | -580.7% | -291.0% | -38.9% | — | — |
| Operating Income | (295.75M) | (340.74M) | (196.7M) | (487.34M) | (555.34M) |
| Operating Margin | -607.8% | -314.2% | -59.5% | — | — |
| Interest Income | 4.6M | 14.77M | 51.51M | 64.64M | 42.9M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 4.6M | 14.77M | 51.51M | 64.64M | 42.9M |
| Income Before Tax | (291.16M) | (325.97M) | (145.19M) | (422.71M) | (512.44M) |
| Pre-Tax Margin | -598.3% | -300.5% | -43.9% | — | — |
| Income Tax Expense | (575K) | 21K | 30K | 68K | 102K |
| Net Income | (290.58M) | (325.99M) | (145.22M) | (422.77M) | (512.54M) |
| Net Margin | -597.2% | -300.6% | -43.9% | — | — |
| EPS (Basic) | (2.39) | (2.60) | (1.06) | (2.57) | (2.97) |
| EPS (Diluted) | (2.39) | (2.60) | (1.06) | (2.57) | (2.97) |
| Weighted Avg Shares | 121.52M | 125.53M | 137.37M | 164.47M | 175.46M |
| Weighted Avg Shares (Diluted) | 121.52M | 125.53M | 137.37M | 164.47M | 175.46M |
Denali Therapeutics Inc.
NASDAQ:DNLI
Intrinsic Alpha fair value
Locked
Current Price
$18.40
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.